Literature DB >> 20679759

Periconception pre-exposure prophylaxis to prevent HIV transmission: benefits, risks, and challenges to implementation.

Lynn T Matthews, Jared M Baeten, Connie Celum, David R Bangsberg.   

Abstract

HIV-serodiscordant couples face complicated choices between fulfilling reproductive desire and risking HIV transmission to their partners and children. Sexual HIV transmission can be dramatically reduced through artificial insemination and sperm washing; however, most couples cannot access these resources. We propose that periconception pre-exposure prophylaxis (PrEP) could offer an important, complementary therapy to harm reduction counseling programs that aim to decrease HIV transmission for couples who choose to conceive. In this paper, we describe the potential benefits of periconception PrEP and define critical points of clarification prior to implementation of PrEP as part of a reproductive health program. We consider sexual transmission risk, current risk reduction options, PrEP efficacy, cost, adherence, resistance, fetal toxicity, and impact of PrEP counseling on entry into health services. We address PrEP in the context of other periconception HIV-prevention strategies, including antiretroviral treatment of the HIV-infected partner. We conclude that, should PrEP prove safe and efficacious in ongoing trials, periconception PrEP may offer a useful approach to minimize risk of HIV transmission for individuals of reproductive age in HIV-endemic countries.

Entities:  

Mesh:

Year:  2010        PMID: 20679759      PMCID: PMC3773599          DOI: 10.1097/QAD.0b013e32833bedeb

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  73 in total

1.  Sexual behavior of HIV discordant couples after HIV counseling and testing.

Authors:  Susan Allen; Jareen Meinzen-Derr; Michele Kautzman; Isaac Zulu; Stanley Trask; Ulgen Fideli; Rosemary Musonda; Francis Kasolo; Feng Gao; Alan Haworth
Journal:  AIDS       Date:  2003-03-28       Impact factor: 4.177

2.  Rates of HIV-1 transmission per coital act, by stage of HIV-1 infection, in Rakai, Uganda.

Authors:  Maria J Wawer; Ronald H Gray; Nelson K Sewankambo; David Serwadda; Xianbin Li; Oliver Laeyendecker; Noah Kiwanuka; Godfrey Kigozi; Mohammed Kiddugavu; Thomas Lutalo; Fred Nalugoda; Fred Wabwire-Mangen; Mary P Meehan; Thomas C Quinn
Journal:  J Infect Dis       Date:  2005-03-30       Impact factor: 5.226

3.  Efficacy of voluntary HIV-1 counselling and testing in individuals and couples in Kenya, Tanzania, and Trinidad: a randomised trial. The Voluntary HIV-1 Counseling and Testing Efficacy Study Group.

Authors: 
Journal:  Lancet       Date:  2000-07-08       Impact factor: 79.321

4.  HIV sexual risk behavior over 36 months of follow-up in the world's first HIV vaccine efficacy trial.

Authors:  Bradford N Bartholow; Susan Buchbinder; Connie Celum; Vamshidar Goli; Beryl Koblin; Michael Para; Michael Marmor; Richard M Novak; Kenneth Mayer; Catherine Creticos; Patti Orozco-Cronin; Vladimir Popovic; Timothy D Mastro
Journal:  J Acquir Immune Defic Syndr       Date:  2005-05-01       Impact factor: 3.731

5.  Syndromic management of sexually-transmitted infections and behaviour change interventions on transmission of HIV-1 in rural Uganda: a community randomised trial.

Authors:  A Kamali; M Quigley; J Nakiyingi; J Kinsman; J Kengeya-Kayondo; R Gopal; A Ojwiya; P Hughes; L M Carpenter; J Whitworth
Journal:  Lancet       Date:  2003-02-22       Impact factor: 79.321

6.  Detection of HIV-1 RNA in seminal plasma samples from treated patients with undetectable HIV-1 RNA in blood plasma.

Authors:  Anne-Geneviève Marcelin; Roland Tubiana; Sidonie Lambert-Niclot; Gilles Lefebvre; Stéphanie Dominguez; Manuela Bonmarchand; Daniele Vauthier-Brouzes; Françoise Marguet; Nathalie Mousset-Simeon; Gilles Peytavin; Catherine Poirot
Journal:  AIDS       Date:  2008-08-20       Impact factor: 4.177

7.  Resistance issues with new nucleoside/nucleotide backbone options.

Authors:  Mark A Wainberg; Dan Turner
Journal:  J Acquir Immune Defic Syndr       Date:  2004-09-01       Impact factor: 3.731

8.  New heterosexually transmitted HIV infections in married or cohabiting couples in urban Zambia and Rwanda: an analysis of survey and clinical data.

Authors:  Kristin L Dunkle; Rob Stephenson; Etienne Karita; Elwyn Chomba; Kayitesi Kayitenkore; Cheswa Vwalika; Lauren Greenberg; Susan Allen
Journal:  Lancet       Date:  2008-06-28       Impact factor: 79.321

Review 9.  Antiretroviral post-exposure prophylaxis (PEP) for occupational HIV exposure.

Authors:  T N Young; F J Arens; G E Kennedy; J W Laurie; G w Rutherford
Journal:  Cochrane Database Syst Rev       Date:  2007-01-24

10.  The impact of pre-exposure prophylaxis (PrEP) on HIV epidemics in Africa and India: a simulation study.

Authors:  Debby C J Vissers; Hélène A C M Voeten; Nico J D Nagelkerke; J Dik F Habbema; Sake J de Vlas
Journal:  PLoS One       Date:  2008-05-07       Impact factor: 3.240

View more
  54 in total

Review 1.  Preexposure prophylaxis for HIV prevention: where have we been and where are we going?

Authors:  Jared M Baeten; Jessica E Haberer; Albert Y Liu; Nirupama Sista
Journal:  J Acquir Immune Defic Syndr       Date:  2013-07       Impact factor: 3.731

2.  Pre-exposure prophylaxis does not affect the fertility of HIV-1-uninfected men.

Authors:  Edwin O Were; Renee Heffron; Nelly R Mugo; Connie Celum; Andrew Mujugira; Elizabeth A Bukusi; Jared M Baeten
Journal:  AIDS       Date:  2014-08-24       Impact factor: 4.177

3.  The cost-effectiveness of pre-exposure prophylaxis for HIV infection in South African women.

Authors:  Rochelle P Walensky; Ji-Eun Park; Robin Wood; Kenneth A Freedberg; Callie A Scott; Linda-Gail Bekker; Elena Losina; Kenneth H Mayer; George R Seage; A David Paltiel
Journal:  Clin Infect Dis       Date:  2012-04-03       Impact factor: 9.079

Review 4.  Oral pre-exposure prophylaxis (PrEP) for prevention of HIV in serodiscordant heterosexual couples in the United States: opportunities and challenges.

Authors:  James M McMahon; Julie E Myers; Ann E Kurth; Stephanie E Cohen; Sharon B Mannheimer; Janie Simmons; Enrique R Pouget; Nicole Trabold; Jessica E Haberer
Journal:  AIDS Patient Care STDS       Date:  2014-07-21       Impact factor: 5.078

Review 5.  Systemic and topical drugs for the prevention of HIV infection: antiretroviral pre-exposure prophylaxis.

Authors:  Jared Baeten; Connie Celum
Journal:  Annu Rev Med       Date:  2012-09-27       Impact factor: 13.739

Review 6.  Antiretrovirals and safer conception for HIV-serodiscordant couples.

Authors:  Lynn T Matthews; Jennifer A Smit; Susan Cu-Uvin; Deborah Cohan
Journal:  Curr Opin HIV AIDS       Date:  2012-11       Impact factor: 4.283

7.  My intention was a child but I was very afraid: fertility intentions and HIV risk perceptions among HIV-serodiscordant couples experiencing pregnancy in Kenya.

Authors:  Kenneth Ngure; Jared M Baeten; Nelly Mugo; Kathryn Curran; Sophie Vusha; Renee Heffron; Connie Celum; Bettina Shell-Duncan
Journal:  AIDS Care       Date:  2014-04-29

Review 8.  Use of antiretrovirals for HIV prevention: what do we know and what don't we know?

Authors:  Jared M Baeten; Robert Grant
Journal:  Curr HIV/AIDS Rep       Date:  2013-06       Impact factor: 5.071

9.  Preexposure prophylaxis for adolescents and young adults at risk for HIV infection: is an ounce of prevention worth a pound of cure?

Authors:  Jill E Pace; George K Siberry; Rohan Hazra; Bill G Kapogiannis
Journal:  Clin Infect Dis       Date:  2012-12-07       Impact factor: 9.079

Review 10.  Oral antiretroviral chemoprophylaxis: current status.

Authors:  Jared Baeten; Connie Celum
Journal:  Curr Opin HIV AIDS       Date:  2012-11       Impact factor: 4.283

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.